Notice: This company has been marked as potentially delisted and may not be actively trading. G1 Therapeutics (GTHX) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrends Get the Latest News and Ratings for GTHX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for G1 Therapeutics and its competitors. Enter your email to sign up for newsletter Sign Up GTHX Analyst Ratings Over TimeTypeCurrent Forecast12/4/23 to 12/3/241 Month Ago11/4/23 to 11/3/243 Months Ago9/5/23 to 9/4/241 Year Ago12/4/22 to 12/4/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy0 Buy rating(s)0 Buy rating(s)0 Buy rating(s)5 Buy rating(s)Hold3 Hold rating(s)3 Hold rating(s)3 Hold rating(s)0 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)1 Sell rating(s)1 Sell rating(s)Consensus Price Target$4.00$4.00$4.00$11.80Forecasted Upside-44.06% Downside-44.06% Downside-43.90% Downside490.00% UpsideConsensus RatingHoldHoldReduceModerate Buy Election warning coming true… (Ad)If you missed it, my emergency election broadcast is now available - watch it before it's too late.Click here to watch it now. GTHX Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History GTHX Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table G1 Therapeutics Stock vs. The CompetitionTypeG1 TherapeuticsMedical CompaniesS&P 500Consensus Rating Score 2.00 2.80 2.50Consensus RatingHoldModerate BuyModerate BuyPredicted Upside-44.06% Downside25,883.41% Upside6.71% UpsideNews Sentiment RatingNeutral NewsSee Recent GTHX NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails8/8/2024HC Wainwright2 of 5 starsE. WhiteSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/7/2024Wedbush4 of 5 starsD. NierengartenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/7/2024Needham & Company LLC2 of 5 starsG. BlumSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold10/6/2023JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeNeutral ➝ Underweight2/13/2023EF Hutton Acquisition Co. ISubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetBuy$35.00 ➝ $19.00+468.86%1/4/2023CitigroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageBuy Get the Latest News and Ratings for GTHX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:16 PM ET. GTHX Forecast - Frequently Asked Questions What is G1 Therapeutics' forecast for 2025? According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for G1 Therapeutics is $4.00, with a high forecast of $6.00 and a low forecast of $3.00. Should I buy or sell G1 Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GTHX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GTHX, but not buy additional shares or sell existing shares. Does G1 Therapeutics's stock price have much downside? According to analysts, G1 Therapeutics's stock has a predicted downside of -44.06% based on their 12-month stock forecasts. Do Wall Street analysts like G1 Therapeutics more than its competitors? Analysts like G1 Therapeutics less than other "medical" companies. The consensus rating for G1 Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GTHX compares to other companies. Stock Forecasts and Research Tools Related Companies Praxis Precision Medicines Stock Forecast Arcutis Biotherapeutics Stock Forecast Arcus Biosciences Stock Forecast Spyre Therapeutics Stock Forecast Syndax Pharmaceuticals Stock Forecast Day One Biopharmaceuticals Stock Forecast Mesoblast Stock Forecast ARS Pharmaceuticals Stock Forecast Ardelyx Stock Forecast Rocket Pharmaceuticals Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. This page (NASDAQ:GTHX) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share G1 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
